Trial Profile
A Study Comparing Effectiveness of Abatacept, Rituximab, Tocilizumab and Anti-tumor Necrosis Factor (TNF) Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Rheumatoid Arthritis (RA) Patients from the Nationwide Swedish Register
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2019
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 08 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism.